Nature Reviews Drug Discovery contents January 2015 Volume 14 Number 1 pp 1-76

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
January 2015 Volume 14 Number 1
Impact Factor 37.231 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Managing diabetes with nanomedicine: challenges and opportunities Omid Veiseh, Benjamin C. Tang, Kathryn A. Whitehead, Daniel G. Anderson & Robert Langer
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Funding Now Available for Collaborative Global Research in Progressive MS Apply TODAY for projects focused on: • Phase 1: Collaborative Planning Award (12 months)  • Phase 2: Collaborative Network Award (4 years) Deadline to apply is January 31, 2015  Visit www.ProgressiveMSAlliance.org to apply and learn more.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Comment: The Innovative Medicines Initiative: an engine for regulatory science Michel Goldman, Nathalie Seigneuret & Hans-Georg Eichler p1 | doi:10.1038/nrd4520 Since its launch in 2008, the Innovative Medicines Initiative has catalysed the formation of many consortia to address challenges in drug development and regulation. As it moves into its second phase, we highlight key outcomes so far and lessons learned. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
FDA reversal sends mixed message to multiple sclerosis community Elie Dolgin p3 | doi:10.1038/nrd4526 The agency's approval of alemtuzumab leaves neurologists wondering when unblinded studies are appropriate for pivotal multiple sclerosis trials. PDF
Anticoagulant antidotes start yielding Phase III promise Dan Jones p5 | doi:10.1038/nrd4527 Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big potential implications for novel oral anticoagulants. PDF
NEWS IN BRIEF EMA greenlights Novartis' first-in-class IL-17 inhibitor Asher Mullard p7 | doi:10.1038/nrd4530 PDF
FDA approves first bispecific Asher Mullard p7 | doi:10.1038/nrd4531 PDF
IN BRIEF Gene therapy pushes the US $1 million price barrier Asher Mullard p7 | doi:10.1038/nrd4532 PDF
BIOBUSINESS BRIEFS Market watch: Evolution of Chinese bioclusters as a framework for investment policies in emerging markets Ajay Gautam p8 | doi:10.1038/nrd4516 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming catalysts in Q1 2015 Armando Uribe p9 | doi:10.1038/nrd4517 PDF
AN AUDIENCE WITH Wayne Koff p10 | doi:10.1038/nrd4528 Wayne Koff, Chief Scientific Officer at the International AIDS Vaccine Initiative, discusses the imminent launch of the Human Vaccines Project. PDF
FROM THE ANALYST'S COUCH Targeting the IL-17–TH17 pathway Hilary S. Bartlett & Ryan P. Million p11 | doi:10.1038/nrd4518 The IL-17–TH17 pathway is a popular target for the treatment of psoriasis and other autoimmune conditions. Bartlett and Million discuss the key agents in the pipeline, several of which are expected to gain approval in the near future. PDF
RESEARCH HIGHLIGHTS Top Anticancer drugs: Finding the perfect combination p13 | doi:10.1038/nrd4524 PDF Biologics: Transferrin' bispecific antibodies across the blood-brain barrier p14 | doi:10.1038/nrd4522 PDF Cancer: mTOR inhibition curbs colorectal cancer p14 | doi:10.1038/nrd4523 PDF Infectious diseases: Two-hit antibody tackles bacteria p15 | doi:10.1038/nrd4525 PDF Cardiovascular diseases: Reversing anticoagulants p16 | doi:10.1038/nrd4521 PDF IN BRIEF Viral diseases: Bacterial flagellin cures rotavirus | Anticancer agents: CDK7 inhibition suppresses MYC-dependent cancer | Cancer: Cancer exosomes promote tumorigenesis | Bone disorders: BET inhibitor prevents bone loss PDF Drug Discovery JOBS of the week Nanomedicine and Molecular Imaging Northwestern University- Feinberg School of Medicine Research Scientist II Broad Institute of MIT and Harvard Postdoctoral Position in Computational Biophysics Institute of Complex Systems, Forschungszentrum Juelich Research Associate - Biochemistry & Molecular Pharmacology University of Massachusetts Graduate Assistant University of Florida More Science jobs from Drug Discovery EVENT Drug Discovery Innovations 17.03.15 Berlin, Germany More science events from
PERSPECTIVES		Top
OUTLOOK A decade of innovation in pharmaceutical R&D: the Chorus model Paul K. Owens, Eyas Raddad, Jeffrey W. Miller, John R. Stille, Kenneth G. Olovich, Neil V. Smith, Rosie S. Jones & Joel C. Scherer p17 | doi:10.1038/nrd4497 Chorus is a small, operationally independent organization within Eli Lilly and Company that specializes in drug development from candidate selection through to clinical proof of concept. Here, we describe its development philosophy, organizational structure, operational model and results in the decade since it was established, which indicate substantial productivity improvements in both time and cost compared to traditional drug development approaches. Abstract | Full Text | PDF
OPINION What do drug transporters really do? Sanjay K. Nigam p29 | doi:10.1038/nrd4461 Potential drug-drug interactions mediated by ATP-binding cassette (ABC) and solute carrier (SLC) transporters are of clinical and regulatory concern, but the endogenous function of these drug transporters is unclear. Nigam describes the evidence that these transporters transport diverse endogenous substrates and could potentially be important in remote communication. Understanding such functions could clarify the roles of these transporters in disease and in drug-metabolite interactions. Abstract | Full Text | PDF
REVIEWS		Top
Managing diabetes with nanomedicine: challenges and opportunities Omid Veiseh, Benjamin C. Tang, Kathryn A. Whitehead, Daniel G. Anderson & Robert Langer p45 | doi:10.1038/nrd4477 The goal of management for both type 1 and type 2 diabetes is the maintenance of blood glucose levels within healthy normoglycaemic ranges. However, safely achieving this goal using current therapeutic approaches has proved challenging. Here, Langer and colleagues review the developing role of nanotechnology in diabetes management, from diagnosis and disease monitoring to therapeutics. Abstract | Full Text | PDF
Muscle wasting in disease: molecular mechanisms and promising therapies Shenhav Cohen, James A. Nathan & Alfred L. Goldberg p58 | doi:10.1038/nrd4467 Muscle atrophy can occur in patients with injuries or denervation of specific muscles, and muscle wasting occurs in patients with systemic diseases, including sepsis and cancer. This Review explains the pathophysiology of muscle wasting and discusses the progress of new therapies to treat this condition. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Grants4Targets: an open innovation initiative to foster drug discovery collaborations Heidrun Dorsch, Alina Elisabeth Jurock, Stefanie Schoepe, Monika Lessl & Khusru Asadullah p74 | doi:10.1038/nrd3078-c2 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.